How much water an IGF-1 LR3 vial takes, what concentration each volume gives, and why a microgram compound in a small vial is the hardest draw to read.
IGF-1 LR3 arrives in the smallest vials on this site — 0.1 mg and 1 mg — and is discussed in micrograms. That combination makes reconstitution arithmetic unusually consequential: the difference between one water volume and another is the difference between a draw of two units and a draw of forty, for exactly the same amount of peptide. This page reports what each volume produces, what a U-100 syringe reads at each concentration, how many amounts a vial holds, and the labelled mixing procedure for a lyophilized peptide, since this compound has none of its own. It reports and does not recommend.
The IGF-1 LR3 calculator runs the same sums for any vial and volume; the sourced dose figures and their provenance are on the IGF-1 LR3 dosage page, and every compound's arithmetic is indexed on the reconstitution hub.
Water per vial and the concentration it gives
One U-100 unit is a hundredth of a millilitre. The 0.5 mL row is not a calculator preset; it is included because it is the volume that keeps a small vial's draws readable without exceeding what the vial holds.
| Vial |
Water added |
Concentration |
Micrograms per unit |
| 0.1 mg |
0.5 mL |
200 mcg/mL |
2 |
| 0.1 mg |
1 mL |
100 mcg/mL |
1 |
| 0.1 mg |
2 mL |
50 mcg/mL |
0.5 |
| 1 mg |
1 mL |
1,000 mcg/mL |
10 |
| 1 mg |
2 mL |
500 mcg/mL |
5 |
| 1 mg |
3 mL |
333 mcg/mL |
3.33 |
| 1 mg |
5 mL |
200 mcg/mL |
2 |
The last row and the first produce the same solution, 200 mcg/mL, from vials that differ tenfold — 5 mL of water into the larger, half a millilitre into the smaller. That is the clearest demonstration of what reconstitution actually decides: concentration is the vial amount divided by the volume, and two entirely different vials meet at the same reading when the division comes out the same.
What each amount comes to in units
The columns are the range circulating for this compound, 20 to 100 mcg a day, as recorded in this site's dosage chart on 2026-09-18.
| Vial and water |
mcg/mL |
20 mcg |
50 mcg |
100 mcg |
| 0.1 mg in 0.5 mL |
200 |
10 units |
25 |
50 |
| 0.1 mg in 1 mL |
100 |
20 |
50 |
100 |
| 0.1 mg in 2 mL |
50 |
40 |
100 |
200 |
| 1 mg in 1 mL |
1,000 |
2 |
5 |
10 |
| 1 mg in 2 mL |
500 |
4 |
10 |
20 |
| 1 mg in 3 mL |
333 |
6 |
15 |
30 |
| 1 mg in 5 mL |
200 |
10 |
25 |
50 |
Read down the 20 mcg column and the spread is twentyfold, from two units to forty, with the same twenty micrograms in every row. A U-100 syringe is marked in whole units and can be read to about half of one, so at the top of that column a half-unit error is a quarter of the amount and at the bottom it is one fortieth. Nothing about the peptide changes across those rows. This is the single most useful thing the arithmetic says about a microgram compound, and it is why the 200 rows exist at all.
The bottom of the column has its own limit: 100 mcg at 50 mcg/mL is 200 units, two full 1 mL syringes for one amount. Between the unreadable and the unholdable, the workable band for this compound is roughly 200 to 1,000 mcg/mL.
How much a vial holds
The vial's milligrams set the number of amounts, and water never changes it:
| Vial |
20 mcg draws |
50 mcg draws |
100 mcg draws |
| 0.1 mg |
5 |
2 |
1 |
| 1 mg |
50 |
20 |
10 |
A 0.1 mg vial is a single 100 mcg amount. That is worth stating plainly, because a vial that holds one draw and a vial that holds fifty are sold under the same name and described with the same microgram figures, and only the milligram line on the label distinguishes them.
The labelled procedure, borrowed from a product that has one
No IGF-1 LR3 vial carries instructions, so what follows is the procedure a regulator approved for a different lyophilized peptide, quoted rather than adapted. EGRIFTA WR's prescribing information directs that the vial is reconstituted with the Bacteriostatic Water for Injection supplied, 1.3 mL into one vial giving 8 mg per mL; that the vial is moved in a circle — swirled — and not shaken; that the solution is inspected and not used if solid particles appear or it is cloudy or coloured; and that unused solution is discarded seven days after mixing. Each of those four elements describes a manufactured product with a known identity, a known fill and a validated shelf life after mixing, which is precisely what a research vial does not have. The general mixing procedure, and storage after it, are covered on medibact.com's reconstitution guide.
What is being dissolved
Two published analyses looked inside vials sold under this name. A German doping-control laboratory characterised the contents of one as Long-R3-IGF-I carrying a six-histidine purification tag joined to the C-terminus by a Leu-Glu linker — a form produced for biochemical studies, the authors concluding that the product may be a by-product of that work and that the effects of the tagged form in humans have not been elucidated. The French anti-doping laboratory, validating a detection method in 2021, reported abundant oxidised forms of the peptide in black-market products, in amounts that forced the method to monitor the oxidised form alongside the native one.
Neither finding changes any arithmetic on this page — a milligram of powder divided by a millilitre of water is a milligram per millilitre whatever the powder turns out to be. They change what the arithmetic is about, which is a different and larger point: concentration is knowable, identity is not, and the second is not improved by being precise about the first.
What this page does not do
It does not state how much IGF-1 LR3 to use, or a frequency, or a route, and it does not tell anyone how to inject anything. It reports water volumes, the concentration each produces, the micrograms in one U-100 unit at each concentration, how many amounts a vial holds, and a labelled procedure from a product that has one. Decisions about administering anything to a person belong with a clinician.
Sources and dates
Opened 2026-09-20: the DailyMed SPL search API for IGF-1 LR3 and mecasermin, with the INCRELEX label from Eton Pharmaceuticals (published 2026-05-20, sections 2.2 and 3) and the EGRIFTA WR prescribing information from Theratechnologies (published 2026-08-03, section 2.2) read in full; PubMed through the NCBI E-utilities for the analogue's name forms in title or abstract (78 records; 25 with the human tag), with the abstracts of PMIDs 33587816 and 20675162 read; the ClinicalTrials.gov v2 API for IGF-1 LR3 as an intervention (no records); MedlinePlus, "Giving an insulin injection" (reviewed 2024-07-21). The circulating microgram figures are as recorded in this site's dosage chart on 2026-09-18. Corrections go to the contact page.